… stable disease, erlotinib was also … III study of erlotinib in patients with NSCLC previously
treated with one or two prior cytotoxic chemotherapy regimens, patients treated with erlotinib …

… III trial to directly compare the efficacy and toxicity between gefitinib and erlotinib in an
enriched patient … In summary, this study demonstrated that both gefitinib and erlotinib showed …

… study was the first head-to-head phase III randomised controlled trial comparing erlotinib with
… The results did not support the hypothesis described in the study design, namely, that the …

… , this study did not show a DFS benefit for erlotinib in patients … , the study failed to demonstrate
a DFS benefit for erlotinib in … A phase III US intergroup trial of adjuvant erlotinib in EGFRm-…

… ] of 443 patients vs none of 445). Serious adverse events were reported in 47 patients (11%)
on erlotinib compared with 34 patients (… Phase III study of immediate compared with delayed …

… The reported 2-year DFS was 89% in the patients who received … higher percentage of patients
with stage II and III disease in the … During the conduct of our study, two phase III trials were …

… II study of single-agent erlotinib as first-line therapy in patients … studies on tumor samples of
patients entered in the study to … The promising efficacy of erlotinib monotherapy in this study …

… In the current study, ∼40% of erlotinib-treated patients in the overall population and exon …
receive any post-study treatment. On the other hand, almost 80% of patients who received first-…

… of erlotinib improves the efficacy of sorafenib in patients with advanced HCC, a phase III trial
… efficacy and safety of first-line sorafenib/erlotinib with sorafenib/placebo in these patients. …

8001 Background: Erlotinib (E), a small-molecule EGFR TKI, is proven to extend survival
versus placebo (P) in 2nd/3rd-line advanced NSCLC. The phase III SATURN study (BO18192) …